Compare Boeing Co (BA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boeing Co vs TG Therapeutics Inc — how do they compare? Boeing Co trades at $231.92 (market cap $184.35B), while TG Therapeutics Inc trades at $49.63 (market cap $7.64B). The key difference: Boeing Co is far larger — about 24.1× TG Therapeutics Inc's market cap, and Boeing Co pays a 0.03% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BA | TGTX | |
|---|---|---|
Market Cap | $184.35B | $7.64B |
Volume | 7,591,579 | — |
Sector | Industrials | Health |
52-Week High | $252.15 | $59.06 |
52-Week Low | $179.12 | $26.94 |
Enterprise Value | $210.23B | $7.84B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $232.14, down 0.28% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company's fundamentals reflect a recovery, with 2025 revenue at $89.46B and net income of $2.24B, though valuation ratios like P/E of 83.9 remain elevated. News highlights Boeing's strategic sale of subsidiaries to Archer Aviation, aiming to streamline operations.
Outlook is cautiously optimistic with a consensus price target of $280.83, implying 21% upside. Key opportunities include production ramp-up and backlog growth, while risks involve high debt, volatile cash flows, and competitive pressures. Investors should monitor execution on profitability targets and macroeconomic impacts on aerospace demand.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
